Ocugen (NASDAQ:OCGN) Given Buy Rating at Chardan Capital

Ocugen (NASDAQ:OCGN)‘s stock had its “buy” rating restated by equities researchers at Chardan Capital in a research note issued on Thursday,Benzinga reports. They currently have a $6.00 price objective on the stock.

Separately, HC Wainwright increased their price objective on shares of Ocugen from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Thursday.

Ocugen Trading Up 2.2 %

Shares of OCGN stock opened at $0.72 on Thursday. Ocugen has a 52-week low of $0.64 and a 52-week high of $2.11. The stock has a market cap of $209.14 million, a price-to-earnings ratio of -3.99 and a beta of 3.82. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.58 and a current ratio of 2.58. The firm has a fifty day moving average of $0.78 and a 200-day moving average of $0.98.

Institutional Investors Weigh In On Ocugen

Hedge funds have recently made changes to their positions in the company. Virtu Financial LLC acquired a new stake in shares of Ocugen during the 4th quarter worth about $32,000. Tower Research Capital LLC TRC increased its position in shares of Ocugen by 309.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 39,848 shares of the company’s stock worth $32,000 after purchasing an additional 30,120 shares in the last quarter. SBI Securities Co. Ltd. acquired a new stake in shares of Ocugen during the 4th quarter worth about $40,000. Two Sigma Securities LLC increased its position in shares of Ocugen by 92.9% during the 4th quarter. Two Sigma Securities LLC now owns 51,909 shares of the company’s stock worth $42,000 after purchasing an additional 25,004 shares in the last quarter. Finally, Gerber Kawasaki Wealth & Investment Management acquired a new stake in shares of Ocugen during the 4th quarter worth about $56,000. Institutional investors and hedge funds own 10.27% of the company’s stock.

Ocugen Company Profile

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.